Dose Comparison of Amino Acids on Growth in Premature Neonates
Information source: Mednax Center for Research, Education and Quality
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malnutrition
Intervention: Parenteral Nutrition (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Mednax Center for Research, Education and Quality Official(s) and/or principal investigator(s): Reese Clark, MD, Principal Investigator, Affiliation: Pediatrix Medical Group, Inc.
Summary
Malnutrition is a common problem in the neonatal intensive care unit. Recent studies
indicate that prematurely born neonates commonly develop a severe nutritional deficit during
the first weeks after birth, referred to as extrauterine growth restriction. Despite an
increase in growth during the second month of hospitalization, many neonates are ultimately
discharged home having grown inadequately. The early nutritional deficit affects weight gain
as well as growth in length and head circumference.
Growth measurements such as weight, length, and head circumference, however, are macroscopic
measures of nutritional status and underestimate the physiologic consequences of prolonged
nutritional deprivation. Energy and micronutrient deficiencies alter growth at a cellular
and tissue level before macroscopic measures are altered. In the brain, for instance, energy
is required for cell division and neuronal growth, glial cell function, and myelination.
Energy deprivation may consequently alter neuronal function and growth, resulting in adverse
neurodevelopmental outcomes.
Immunocompetence also appears to be sensitive to the untoward effects of energy and
nutritional deficiency. Malnourished neonates often exhibit immune deficiencies related to
inadequate protein intake that compound an already immature immune system. Such
immunodeficiency results in susceptibility to infectious agents that creates substantial
morbidity and mortality to the course of intensive care for premature infants.
A recent study suggests that postnatal malnutrition and growth restriction are inevitable if
current recommended dietary intakes are followed. Multicenter studies show that variation in
dietary intake accounts for 45% of the variation in growth. Hence, efforts have focused on
determining whether nutritional deficiency and the observed growth restriction of premature
infants can be prevented through the use of more optimal nutritional intake. In addition,
inadequate protein support may be a primary cause for growth failure.
Based on animal studies showing high in utero amino acid flux observed during the latter
phase of gestation, Thureen et al have suggested the use of higher doses of amino acid
supplementation in order to minimize growth restriction and improve outcomes of premature
infants. However there are no large human trials that demonstrate that this approach
promotes better growth or that it is safe. While small doses of amino acids may be
inadequate to promote normal growth, high doses may lead to elevated serum amino acid levels
and increase the occurrence of toxicity. Through the implementation of a multicenter,
randomized trial and tandem mass spectrometry, the investigators propose to evaluate the
effects of two distinct strategies of amino acid supplementation on serum amino acid
profiles and growth of premature infants during the first 28 days of life.
Clinical Details
Official title: Randomized Control Trial Evaluating the Effect of Two Different Doses of Amino Acids on Growth and Serum Amino Acids in Premature Neonates Admitted to the NICU
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: The primary outcome is growth velocity for first 28 days of life calculated as: weight gain, head circumference, length
Secondary outcome: Secondary outcomes include serum amino acid profiles measured on: day 7 of life, day 28 of life
Eligibility
Minimum age: N/A.
Maximum age: 48 Hours.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Documentation of informed consent
- Inborn
- Gestational age between 23 weeks and 0/7 days and 29 weeks and 6/7 days
- If subject is transferred to another hospital, the ability to obtain follow-up data
on outcomes
- No major anomalies
- Ability to begin parenteral nutrition within the first 48 hours after birth
Exclusion Criteria:
- Outborn
- Gestational age < 23 weeks or >= 30 weeks
- Any major congenital anomalies
Locations and Contacts
McLeod Regional Medical Center, Florence, South Carolina 29506, United States
Additional Information
Related publications: Thureen PJ, Melara D, Fennessey PV, Hay WW Jr. Effect of low versus high intravenous amino acid intake on very low birth weight infants in the early neonatal period. Pediatr Res. 2003 Jan;53(1):24-32.
Starting date: August 2005
Last updated: September 27, 2006
|